Sabby Management’s Arcadia Biosciences RKDA Stock Holding History

Sabby Management’s Portfolio RKDA Stock Details RKDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7	Closed	-$29K	–	135
2022 Q2	$29K	Sell	7 -7	-50%	-$322	0.02%	113
2022 Q1	$77K	Buy	14 +1	+8%	+$48	0.01%	123
2021 Q4	$56K	Sell	13 -70	-84%	-$4.56K	0.01%	167
2021 Q3	$684K	Sell	83 -126	-60%	-$11.8K	0.09%	106
2021 Q2	$2.48M	Buy	209 +113	+118%	+$12.3K	0.35%	40
2021 Q1	$1.05M	Buy	96 +90	+1,500%	+$11K	0.2%	78
2020 Q4	$61K	Buy	+6	New	+$732	0.01%	98

Other funds holding RKDA

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BWM

Bullock Wealth Management Bloomington, Indiana $231M AUM

Sabby Management's RKDA Position: Q2 2026 in Review

Sabby Management sold out of Arcadia Biosciences (RKDA) in Q2 2026, closing a stake of 114,554 shares — an estimated $158K sold.

Sabby Management first reported a position in RKDA in Q1 2018 and held it in 17 quarters. The position peaked at $3.61M in Q1 2018. 18 funds tracked by Wall St. Rank hold RKDA as of Q2 2026.

Sabby Management reported no remaining Arcadia Biosciences position as of Q2 2026 after selling out during the quarter.
Sabby Management sold 114,554 Arcadia Biosciences shares in Q2 2026, an estimated $158K.
Sabby Management first reported a position in Arcadia Biosciences in Q1 2018 and held it in 17 quarters.
Sabby Management's Arcadia Biosciences position peaked at $3.61M in Q1 2018.
18 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2026.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.